Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Regeneron and bluebird bio enter cell therapy pact

Executive Summary

Regeneron Pharmaceuticals Inc. and bluebird bio Inc. will lean on each other’s platform discoveries to together discover and develop antibodies and T-cell receptors directed against tumor-specific proteins and peptides.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • Co-Promotion

Related Companies

Advertisement
UsernamePublicRestriction

Register